Inovio Abandons Lassa, MERS Vaccines Shortly After Ending COVID-19 Booster Work

 
• By Joseph Haas

Two clinical-stage vaccine candidates for Lassa Fever and MERS, funded by CEPI, are being discontinued, but Inovio will continue its focus on DNA medicines for HPV-related conditions and cancer.

Halt
Inovio is halting work on two vaccines partnered with CEPI • Source: Shutterstock

More from Strategy

More from Business